Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Zimmer Biomet Holdings / Equity Bottom-Up

<ul><li>Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges.</li><li>The company, a major player in the medical devices sector, particularly in orthopedics, navigated through intricate dynamics, including an ERP implementation issue that significantly impacted its operations.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges.The company, a major player in the medical devices sector, particularly in orthopedics, navigated through intricate dynamics, including an ERP implementation issue that significantly impacted its operations.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Zimmer Biomet Holdings: An Analysis Of Its Enhanced Product Portfolio

<ul><li>Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic advancements, though it faced specific challenges during the period.</li><li>The company reported a year-over-year revenue growth of 5.6% on a constant currency basis for the second quarter of 2024.</li><li>This marks Zimmer Biomet's tenth consecutive quarter of mid-single-digit or higher growth.</li></ul>

Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic advancements, though it faced specific challenges during the period.The company reported a year-over-year revenue growth of 5.6% on a constant currency basis for the second quarter of 2024.This marks Zimmer Biomet's tenth consecutive quarter of mid-single-digit or higher growth.

Zimmer Biomet Holdings Inc.: Enhanced Focus on Robotic & Cementless Technologies & Global Expansion! - Major Drivers

<ul><li>Zimmer Biomet’s first quarter 2024 earnings were positive and the management displayed confidence in the company's 2024 outlook based on strong Q1 performances that surpassed expectations.</li><li>The company reported a 4.4% constant currency revenue growth despite sizeable day rate headwinds and challenging comparisons to the previous year.</li><li>This solid revenue performance was attributed to favourable end markets coupled with strong execution across their global organization.</li></ul>

Zimmer Biomet’s first quarter 2024 earnings were positive and the management displayed confidence in the company's 2024 outlook based on strong Q1 performances that surpassed expectations.The company reported a 4.4% constant currency revenue growth despite sizeable day rate headwinds and challenging comparisons to the previous year.This solid revenue performance was attributed to favourable end markets coupled with strong execution across their global organization.

Zimmer Biomet Holdings: A Tale of Customer Conversion & Gaining Market Share! - Major Drivers

<ul><li>Zimmer Biomet, a leading player in the medical devices industry, presented its fourth quarter 2023 earnings with a buoyant attitude, displaying solid evidence of robust financial performance and operational progress.</li><li>Impressively, the firm underscored the notable growth in its constant currency revenue, which appreciated 7.5%, with adjusted earnings per share (EPS) escalating almost 9.5% over the year.</li><li>Also noteworthy was the almost $1 billion in free cash flow generated during the period, even amid fluctuations in inventory management.</li></ul>

Zimmer Biomet, a leading player in the medical devices industry, presented its fourth quarter 2023 earnings with a buoyant attitude, displaying solid evidence of robust financial performance and operational progress.Impressively, the firm underscored the notable growth in its constant currency revenue, which appreciated 7.5%, with adjusted earnings per share (EPS) escalating almost 9.5% over the year.Also noteworthy was the almost $1 billion in free cash flow generated during the period, even amid fluctuations in inventory management.

Zimmer Biomet Holdings: Can It Maintain Its Robust Competitive Position In Orthopedics? - Major Drivers

<ul><li>In the latest quarterly result, Zimmer managed on-par net sales amounted to $1.754 billion, reflecting a 5% increase on a reported basis, with a concurrent 4.7% rise when excluding the impact of foreign currency.</li><li>In terms of cash and liquidity, operating cash flows amounted to $338 million, with free cash flow at $189 million for the quarter.</li><li>Free cash flow for the year is expected to range between $950 million and $1 billion.</li></ul>

In the latest quarterly result, Zimmer managed on-par net sales amounted to $1.754 billion, reflecting a 5% increase on a reported basis, with a concurrent 4.7% rise when excluding the impact of foreign currency.In terms of cash and liquidity, operating cash flows amounted to $338 million, with free cash flow at $189 million for the quarter.Free cash flow for the year is expected to range between $950 million and $1 billion.

Zimmer Biomet Holdings: Navigating International Markets – A Strategy for Growth Amid Challenges! - Major Drivers

United States

Zimmer Biomet Holdings, Inc. designs, develops, manufactures, and markets medical equipment. The Company offers orthopedic, dental, and spinal reconstructive implants, as well as bone cement and related surgical products. Zimmer Biomet Holdings serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zimmer Biomet Holdings (ZBH UN)

Zimmer Biomet Holdings: An Analysis Of Its Enhanced Product Portfolio

Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges. The company, a major...

Baptista Research

Zimmer Biomet Holdings Inc.: Enhanced Focus on Robotic & Cementless Technologies & Global Expansion! - Major Drivers

Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic...

Baptista Research

Zimmer Biomet Holdings: Can It Maintain Its Robust Competitive Position In Orthopedics? - Major Drivers

Zimmer Biomet, a leading player in the medical devices industry, presented its fourth quarter 2023 earnings with a buoyant attitude, displaying...

Baptista Research

Zimmer Biomet Holdings: Navigating International Markets – A Strategy for Growth Amid Challenges! - Major Drivers

In the latest quarterly result, Zimmer managed on-par net sales amounted to $1.754 billion, reflecting a 5% increase on a reported basis, with a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Zimmer Biomet Holdings: An Analysis Of Its Enhanced Product Portfolio

Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges. The company, a major...

Baptista Research

Zimmer Biomet Holdings Inc.: Enhanced Focus on Robotic & Cementless Technologies & Global Expansion! - Major Drivers

Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic...

Baptista Research

Zimmer Biomet Holdings: A Tale of Customer Conversion & Gaining Market Share! - Major Drivers

Zimmer Biomet’s first quarter 2024 earnings were positive and the management displayed confidence in the company's 2024 outlook based on strong Q1...

Baptista Research

Zimmer Biomet Holdings: Can It Maintain Its Robust Competitive Position In Orthopedics? - Major Drivers

Zimmer Biomet, a leading player in the medical devices industry, presented its fourth quarter 2023 earnings with a buoyant attitude, displaying...

Baptista Research

Zimmer Biomet Holdings: Navigating International Markets – A Strategy for Growth Amid Challenges! - Major Drivers

In the latest quarterly result, Zimmer managed on-par net sales amounted to $1.754 billion, reflecting a 5% increase on a reported basis, with a...

Baptista Research